Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase

被引:27
作者
Selness, Shaun R. [1 ]
Devraj, Rajesh V. [1 ]
Monahan, Joseph B. [2 ]
Boehm, Terri L. [1 ]
Walker, John K. [1 ]
Devadas, Balekudru [1 ]
Durley, Richard C. [1 ]
Kurumbail, Ravi [3 ]
Shieh, Huey [3 ]
Xing, Li [3 ]
Hepperle, Michael [1 ]
Rucker, Paul V. [1 ]
Jerome, Kevin D. [1 ]
Benson, Alan G. [1 ]
Marrufo, Laura D. [1 ]
Madsen, Heather M. [1 ]
Hitchcock, Jeff [1 ]
Owen, Tom J. [1 ]
Christie, Lance [1 ]
Promo, Michele A. [1 ]
Hickory, Brian S. [1 ]
Alvira, Edgardo [1 ]
Naing, Win [1 ]
Blevis-Bal, Radhika [1 ]
机构
[1] Pfizer Corp, Dept Med Chem, Chesterfield, MO 63017 USA
[2] Pfizer Corp, Inflammat Biol, Chesterfield, MO 63017 USA
[3] Pfizer Corp, Struct & Computat Chem, Chesterfield, MO 63017 USA
关键词
p38; kinase; Pyridinones; RHEUMATOID-ARTHRITIS;
D O I
10.1016/j.bmcl.2009.08.082
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The identification and evolution of a series of potent and selective p38 inhibitors is described. p38 inhibitors based on a N-benzyl pyridinone high-throughput screening hit were prepared and their SAR explored. Their design was guided by ligand bound co-crystals of p38 alpha. These efforts resulted in the identification of 12r and 19 as orally active inhibitors of p38 with significant efficacy in both acute and chronic models of inflammation. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5851 / 5856
页数:6
相关论文
共 12 条
  • [1] Pyrimidinylimidazole inhibitors of CSBP/P37 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes
    Adams, JL
    Boehm, JC
    Kassis, S
    Gorycki, PD
    Webb, EF
    Hall, R
    Sorenson, M
    Lee, JC
    Ayrton, A
    Griswold, DE
    Gallagher, TF
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (22) : 3111 - 3116
  • [2] CYTOKINES AND CYTOKINE INHIBITORS OR ANTAGONISTS IN RHEUMATOID-ARTHRITIS
    AREND, WP
    DAYER, JM
    [J]. ARTHRITIS AND RHEUMATISM, 1990, 33 (03): : 305 - 315
  • [3] BEMIS G, 2008, Patent No. 7365072
  • [4] CASTILLO S, 1982, B SOC CHIM FR II-CH, P257
  • [6] FIRESTEIN GS, 1990, J IMMUNOL, V144, P3347
  • [7] Foster ML, 2000, DRUG NEWS PERSPECT, V13, P488
  • [8] Jackson Paul F., 2002, Current Topics in Medicinal Chemistry, V2, P1011, DOI 10.2174/1568026023393372
  • [9] A PROTEIN-KINASE INVOLVED IN THE REGULATION OF INFLAMMATORY CYTOKINE BIOSYNTHESIS
    LEE, JC
    LAYDON, JT
    MCDONNELL, PC
    GALLAGHER, TF
    KUMAR, S
    GREEN, D
    MCNULTY, D
    BLUMENTHAL, MJ
    HEYS, JR
    LANDVATTER, SW
    STRICKLER, JE
    MCLAUGHLIN, MM
    SIEMENS, IR
    FISHER, SM
    LIVI, GP
    WHITE, JR
    ADAMS, JL
    YOUNG, PR
    [J]. NATURE, 1994, 372 (6508) : 739 - 746
  • [10] Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
    Rutgeerts, P
    D'Haens, G
    Targan, S
    Vasiliauskas, E
    Hanauer, SB
    Present, DH
    Mayer, L
    Van Hogezand, RA
    Braakman, T
    DeWoody, KL
    Schaible, TF
    Van Deventer, SJH
    [J]. GASTROENTEROLOGY, 1999, 117 (04) : 761 - 769